Dec. 7, 2020 13:00 UTC Enrollment commenced in the MGTA-145 Phase 2 clinical trial of autologous transplant of multiple myeloma patients at Stanford University Oral presentation of Phase 1 clinical data presented at the 62nd American Society of Hematology (ASH) Annual Meeting confirming MGTA-145 achieved proof-of concept: all safety and efficacy endpoints met and mobilized cells demonstrated functional superiority over other mobilization approaches in preclinical studies Preclinical data from MGTA-117, the first targeted antibody-drug conjugate (ADC) from the Magenta platform, continue to indicate that it is an effective, potent conditioning agent with the potential to improve transplant outcomes in patients with blood cancers and genetic diseases Magenta expects to provide additional updates on its programs and clinical plans in early 2021 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed Phase 1 clinical trial as well as development updates for its MGTA-145 stem cell mobilization therapy, including commencement of enrollment in a Phase 2 clinical trial in multiple myeloma, and its plans for a Phase 2 clinical trial in allogeneic stem cell transplant for patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndrome (MDS)